{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:29:52Z","timestamp":1787009392108,"version":"build-2736575974"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2002,4,1]]},"DOI":"10.1093\/ndt\/17.4.597","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:42:52Z","timestamp":1027708972000},"page":"597-601","source":"Crossref","is-referenced-by-count":64,"title":["Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria"],"prefix":"10.1093","volume":"17","author":[{"given":"Priscilla","family":"Kincaid\u2010Smith","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Fairley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Packham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2002,4]]},"reference":[{"key":"key\n\t\t\t\t20180110112221_R1","doi-asserted-by":"crossref","unstructured":"Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: From ACEI to angiotensin II antagonists. Kidney Int2000; 57: 1803\u20131817","DOI":"10.1046\/j.1523-1755.2000.00031.x"},{"key":"key\n\t\t\t\t20180110112221_R2","doi-asserted-by":"crossref","unstructured":"Lewis E, Hunsicker L, Clarke W et al. Renoprotective effect of the angiotension\u2010receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. New Engl J Med2001; 345: 851\u2013860","DOI":"10.1056\/NEJMoa011303"},{"key":"key\n\t\t\t\t20180110112221_R3","doi-asserted-by":"crossref","unstructured":"Brenner B, Cooper M, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. New Engl J Med2001; 345: 861\u2013869","DOI":"10.1056\/NEJMoa011161"},{"key":"key\n\t\t\t\t20180110112221_R4","doi-asserted-by":"crossref","unstructured":"Parving H\u2010H, Lehnert H, Brochner\u2010Mortensen J, Gomis R, Anderson S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with Type 2 diabetes. New Engl J Med2001; 345: 870\u2013878","DOI":"10.1056\/NEJMoa011489"},{"key":"key\n\t\t\t\t20180110112221_R5","doi-asserted-by":"crossref","unstructured":"Peterson JC, Adler S, Burkart JM et al. Blood pressure control, proteinuria and the progression of renal disease. The modification of diet in renal disease study. Ann Intern Med1995; 123: 754\u2013762","DOI":"10.7326\/0003-4819-123-10-199511150-00003"},{"key":"key\n\t\t\t\t20180110112221_R6","doi-asserted-by":"crossref","unstructured":"Agarwal R. Add\u2010on angiotensin receptor blockade with maximised ACE inhibition. Kidney Int2001; 59: 2282\u20132289","DOI":"10.1046\/j.1523-1755.2001.00745.x"},{"key":"key\n\t\t\t\t20180110112221_R7","doi-asserted-by":"crossref","unstructured":"Ruggenenti P, Perna A, Gherardi G, Benini R, Remuzzi G. Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. Am J Kidney Dis2000; 35: 1155\u20131165","DOI":"10.1016\/S0272-6386(00)70054-0"},{"key":"key\n\t\t\t\t20180110112221_R8","doi-asserted-by":"crossref","unstructured":"Exner D, Dries D, Domanski M, Cohn J. Lesser response to angiotensin\u2010converting enzyme inhibitor therapy in black compared with white patients with left ventricular hypertrophy. New Engl J Med2001; 344: 1351\u20131357","DOI":"10.1056\/NEJM200105033441802"},{"key":"key\n\t\t\t\t20180110112221_R9","doi-asserted-by":"crossref","unstructured":"Agoda LY, Appel L, Bakis G et al. Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: randomised controlled trial. J Am Med Assoc2001; 285: 2719\u20132728","DOI":"10.1001\/jama.285.21.2719"},{"key":"key\n\t\t\t\t20180110112221_R10","doi-asserted-by":"crossref","unstructured":"Kincaid\u2010Smith PS, Fairley KF. Continuing fall in proteinuria after 6 months of combined angiotension converting enzyme inhibitor and angiotensin II receptor antagonist with disappearance of proteinuria of 6\u201321 years duration in 5 patients. J Am Soc Nephrol2001; 12: 75A","DOI":"10.1046\/j.1440-1797.2002.00007-1-100.x"},{"key":"key\n\t\t\t\t20180110112221_R11","doi-asserted-by":"crossref","unstructured":"Ruilope LM, Aldigier JC, Ponticelli C, Oddon\u2010Stock P, Botteri F, Mann JF. Safety of the combination of Valsartan and Benazepril in patients with chronic renal disease. J Hypertension2000; 18: 89\u201395","DOI":"10.1097\/00004872-200018010-00013"},{"key":"key\n\t\t\t\t20180110112221_R12","doi-asserted-by":"crossref","unstructured":"Russo D, Pisani A, Balletta MM, De Nicola L, Savino FA, Andreucci M et al. Additive antiproteinuric effect of converting enzyme inhibitor and losartan in normotensive patients with IgA nephropathy. Am J Kidney Dis1999; 33: 851\u2013856","DOI":"10.1016\/S0272-6386(99)70416-6"},{"key":"key\n\t\t\t\t20180110112221_R13","doi-asserted-by":"crossref","unstructured":"Zoccali C, Valvo E, Russo D, Panichi V, Zuccala A. Antiproteinuric effect of Losartan in patients with chronic renal disease. Nephrol Dial Transplant1997; 12: 234\u2013235","DOI":"10.1093\/oxfordjournals.ndt.a027738"},{"key":"key\n\t\t\t\t20180110112221_R14","doi-asserted-by":"crossref","unstructured":"Mogensen CE, Neldam S, Tikkanen I, Oren S, Viskoper R, Watts R et al. Randomised controlled trial of dual blockade of renin\u2010angiotensin system in patients with hypertension, microalbuminuria and non\u2010insulin dependent diabetes: the candesartan and lisinopril microalbimiuria (CALM) study. BMJ2000; 321: 1440\u20131444","DOI":"10.1136\/bmj.321.7274.1440"},{"key":"key\n\t\t\t\t20180110112221_R15","doi-asserted-by":"crossref","unstructured":"Ravid M, Brosh D, Levi Z, Bar\u2010Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with Type 2 diabetes mellitus: a randomised controlled trial. Ann Intern Med1998; 128: 982\u2013988","DOI":"10.7326\/0003-4819-128-12_Part_1-199806150-00004"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/17\/4\/597\/23372051\/170597.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T04:00:59Z","timestamp":1583294459000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/ndt\/article\/17\/4\/597\/1835781"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2002,4]]},"published-print":{"date-parts":[[2002,4,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/17.4.597","relation":{},"ISSN":["1460-2385","0931-0509"],"issn-type":[{"value":"1460-2385","type":"electronic"},{"value":"0931-0509","type":"print"}],"subject":[],"published-other":{"date-parts":[[2002,4]]},"published":{"date-parts":[[2002,4,1]]}}}